Efalizumab

被引：14

作者：

Chacko, Manju

Weinberg, Jeffrey M.

机构：

[1] Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Dermatol, New York, NY 10025 USA

[2] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA

来源：

DERMATOLOGIC THERAPY | 2007年 / 20卷 / 04期

关键词：

biologic; efalizumab; immune modulators; psoriasis;

D O I：

10.1111/j.1529-8019.2007.00139.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Efalizumab is a novel immunomodulator that blocks T-cell migration and activation. The drug was initially approved in October 2003 for the treatment of adult patients with chronic moderate to severe plaque psoriasis. This review will discuss the efficacy and safety data for efalizumab in the treatment of psoriasis. In clinical use, efalizumab has utility as a first-line biologic therapy for plaque psoriasis, as well as a first-line choice for hand and foot psoriasis, overweight patients, and those who have had inadequate response to a TNF inhibitor. In addition, several off-label applications of efalizumab will be reviewed.

引用

页码：265 / 269

页数：5

共 16 条

[1] Oral erosive lichen planus treated with efalizumab [J].